Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Mylan, Genentech and Roche Reach Agreement on Biosimilar Cancer Drug

XTALKS VITALS NEWS

Handshake

The global license will allow Mylan to market its trastuzumab product in multiple countries around the world, excluding Brazil, Mexico and Japan.

Share this!

March 15, 2017 | by Sarah Hand, M.Sc.

Mylan’s biosimilar version of the breast cancer drug, Herceptin, may soon be available, thanks to a settlement reached between the pharmaceutical company and the makers of the reference biologic, Genentech and Roche. The global license will allow Mylan to market its trastuzumab product in multiple countries around the world, excluding Brazil, Mexico and Japan.

A condition of the agreement required Mylan to drop two patent litigation cases against Genentech, regarding Herceptin. Mylan has already submitted an application for the Herceptin biosimilar to the US Food and Drug Administration (FDA), and the company hopes to be the first to introduce the trastuzumab drug to the US market.

“There is an unmet need for access to more affordable versions of biologic products such as trastuzumab,” said Heather Bresch, CEO of Mylan. “We look forward to enhancing access to this important treatment option, which complements our comprehensive cancer care offerings, in the US and around the world.”



Mylan is developing trastuzumab alongside Biocon, along with five other biologic products. While Mylan has sole commercialization rights for the biosimilar in the US, Canada, Japan, Australia, New Zealand and in the European Union, Biocon will work alongside Mylan to commercialize the cancer treatment in the rest of the world.

Mylan is also awaiting European Medicines Agency (EMA) approval for trastuzumab. Currently, the biosimilar is sold in 14 emerging markets around the world.

“With 16 biosimilar products in development,” said Bresch, “we believe Mylan has one of the industry's broadest portfolios of biosimilars and that we will be a leader in bringing high-quality biosimilar products to market given our ability not only to develop and manufacture such complex products, but also to navigate the intricate regulatory and legal environment and successfully commercialize these products on a global basis.”

In 2016, sales of Herceptin reached nearly $4.5 billion in the US and European markets. In addition to its pending regulatory submission for trastuzumab, Mylan and Biocon have also applied for approval for their biosimilar of Amgen’s Neulasta.


Keywords: Biosimilar, Breast Cancer, Biologic


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Study Finds Hospital-Acquired Anemia Linked with Poorer Patient Outcomes

May 19, 2017 - New research conducted at UT Southwestern Medical Center has found that one in three patients admitted to hospital develop anemia as a result.

Featured In: Life Science News


Scott Gottlieb Takes the Helm of the FDA

May 18, 2017 - One of the first things on his regulatory agenda is to address drug pricing – a hot topic in the US pharmaceutical industry today.

Featured In: Pharmaceutical News


Opioid Prescriptions for Minor Injuries Contribute to Growing Epidemic

May 18, 2017 - While many assume that patients prescribed large quantities of opioid drugs – such as oxycodone – for chronic pain are at the highest risk of abuse and dependence, new research suggests that small prescriptions for these narcotic painkillers could be just as dangerous.

Featured In: Drug Safety News


LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations


Respiratory Endpoints, Scientific Leadership and the Asia-Pacific Region


Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges


Enabling Patient-Centric Digital Transformation in Pharma and Biotech


Copyright © 2016-2017 Honeycomb Worldwide Inc.